GeneDx Holdings Corp. (NASDAQ:WGS) Shares Bought by EntryPoint Capital LLC

EntryPoint Capital LLC increased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 32.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,141 shares of the company’s stock after acquiring an additional 2,953 shares during the period. GeneDx comprises 0.4% of EntryPoint Capital LLC’s holdings, making the stock its 6th largest holding. EntryPoint Capital LLC’s holdings in GeneDx were worth $933,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Prudential Financial Inc. bought a new position in shares of GeneDx in the 4th quarter valued at $7,938,000. Emerald Advisers LLC bought a new position in GeneDx in the fourth quarter valued at about $7,057,000. Vanguard Group Inc. raised its stake in GeneDx by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock worth $77,337,000 after acquiring an additional 156,768 shares in the last quarter. LPL Financial LLC bought a new position in shares of GeneDx in the fourth quarter worth about $2,738,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of GeneDx in the 4th quarter valued at approximately $200,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $103.19 on Tuesday. The firm has a market cap of $2.90 billion, a PE ratio of -52.65 and a beta of 1.91. GeneDx Holdings Corp. has a 52 week low of $8.10 and a 52 week high of $115.60. The firm’s fifty day moving average is $85.25 and its 200-day moving average is $72.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Buying and Selling at GeneDx

In related news, CEO Katherine Stueland sold 51,420 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the completion of the sale, the chief executive officer now owns 1,720 shares of the company’s stock, valued at $162,505.60. This trade represents a 96.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Kevin Feeley sold 3,749 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $96.71, for a total value of $362,565.79. Following the completion of the transaction, the chief financial officer now directly owns 8,492 shares in the company, valued at approximately $821,261.32. This trade represents a 30.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,735 shares of company stock valued at $11,719,787. 27.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.